Biological variation of homeostasis model assessment-derived insulin resistance in type 2 diabetes

被引:36
作者
Jayagopal, V
Kilpatrick, ES
Jennings, PE
Hepburn, DA
Atkin, SL
机构
[1] Hull Royal Infirm, Michael White Ctr Diabet & Endocrinol, Dept Clin Biochem, Kingston Upon Hull HU3 2RW, N Humberside, England
[2] Univ Hull, Dept Med, Kingston Upon Hull HU6 7RX, N Humberside, England
[3] York District Gen Hosp, Dept Med, York, N Yorkshire, England
关键词
D O I
10.2337/diacare.25.11.2022
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE - Individuals with type 2 diabetes are particularly vulnerable to cardiovascular disease. Insulin resistance is a major determinant of this increased risk and is a potential therapeutic target. This study was undertaken to establish the natural biological variation of insulin resistance in individuals with type 2 diabetes. RESEARCH DESIGN AND METHODS - The biological variation of insulin resistance was assessed by measuring insulin resistance at 4-day intervals on 10 consecutive occasions in 12 postmenopausal women with diet-controlled type 2 diabetes and in I 1 weight- and age-matched postmenopausal women without type 2 diabetes. Insulin resistance was derived using the homeostasis model assessment for insulin resistance (HOMA-IR) method. RESULTS - The distribution of HOMA-IR was log Gaussian in the type 2 diabetic study group and Gaussian in the control group. The HOMA-IR in the type 2 diabetic group was significantly greater than that of the control group (mean +/- SD: 4.33 +/- 2.3 vs. 2.11 +/- 0.79 units, P = 0.001). After accounting for analytical variation, the mean intraindividual variation was also substantially greater in the type 2 diabetic group than in the control group (mean 1.05 vs. 0.15, P = 0.001). Consequently, at any level of HOMA-IR, a subsequent sample must, increase by >90% or decrease by >47% to be considered significantly different from the first. CONCLUSIONS - HOMA-IR is significantly greater and more variable for individuals with type 2 diabetes. Therefore, this inherent variability needs to be accounted for in studies evaluating therapeutic reduction of HOMA-IR in this group.
引用
收藏
页码:2022 / 2025
页数:4
相关论文
共 25 条
[1]   Ethnic differences in insulin resistance and its consequences in older Mexican American and non-hispanic white women [J].
Aguirre, MA ;
Jones, CNO ;
Pei, D ;
Villa, ML ;
Reaven, GM .
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 1997, 52 (01) :M56-M60
[2]   THE DAWN PHENOMENON - A COMMON OCCURRENCE IN BOTH NON-INSULIN-DEPENDENT AND INSULIN-DEPENDENT DIABETES-MELLITUS [J].
BOLLI, GB ;
GERICH, JE .
NEW ENGLAND JOURNAL OF MEDICINE, 1984, 310 (12) :746-750
[3]   Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity - Studies in subjects with various degrees of glucose tolerance and insulin sensitivity [J].
Bonora, E ;
Saggiani, F ;
Targher, G ;
Zenere, MB ;
Alberiche, M ;
Monauni, T ;
Bonadonna, RC ;
Muggeo, M .
DIABETES CARE, 2000, 23 (01) :57-63
[4]   DETERIORATION OF GLUCOSE-TOLERANCE WITH AGE - THE ROLE OF INSULIN RESISTANCE - REVIEW [J].
BROUGHTON, DL ;
TAYLOR, R .
AGE AND AGEING, 1991, 20 (03) :221-225
[5]   EFFECTS OF LOW-DOSES OF TRANSDERMAL 17-BETA-ESTRADIOL ON CARBOHYDRATE-METABOLISM IN POSTMENOPAUSAL WOMEN [J].
CAGNACCI, A ;
SOLDANI, R ;
CARRIERO, PL ;
PAOLETTI, AM ;
FIORETTI, P ;
MELIS, GB .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 74 (06) :1396-1400
[6]   Effect of postmenopausal hormone therapy on glucose and insulin concentrations [J].
Espeland, MA ;
Hogan, PE ;
Fineberg, SE ;
Howard, G ;
Schrott, H ;
Waclawiw, MA ;
Bush, TL .
DIABETES CARE, 1998, 21 (10) :1589-1595
[7]   Measurements of insulin-mediated glucose disposal are stable over time [J].
Facchini, F ;
Humphreys, MH ;
Jeppesen, J ;
Reaven, GM .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (05) :1567-1569
[8]   HYPERINSULINEMIA - THE KEY FEATURE OF A CARDIOVASCULAR AND METABOLIC SYNDROME [J].
FERRANNINI, E ;
HAFFNER, SM ;
MITCHELL, BD ;
STERN, MP .
DIABETOLOGIA, 1991, 34 (06) :416-422
[9]   Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus - A randomized controlled trial [J].
Fonseca, V ;
Rosenstock, J ;
Patwardhan, R ;
Salzman, A .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (13) :1695-1702
[10]  
FRASER CG, 1989, CRIT REV CL LAB SCI, V27, P409